A Phase 3 Multinational, Randomized, Double-Blind, Placebo Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP 9001 in Subjects With Duchenne Muscular Dystrophy" ("Study"); Sarepta Protocol Number SRP-9001-301

Administered By

Awarded By

Contributors

Start/End

  • March 4, 2022 - December 31, 2022